Effect of Implementing Prevention Measures Through Personalized Information in Emergency Departments on Adherence to Prevention Measures (PREV-URG)
Effect of Implementing Prevention Measures Through Personalized Information in Emergency Departments on Adherence to Prevention Measures: A Multicenter, Randomized Controlled Exploratory Trial
Prevention, a cornerstone of public health, remains underutilized despite its proven effectiveness. Vaccinations, screenings, reduced consumption of toxic substances, and healthy lifestyle and dietary habits can significantly reduce morbidity and mortality. However, participation rates in France remain low compared to those of neighboring European countries, particularly with regard to cancer screenings and vaccination coverage. A lack of information, motivation, or unequal access hinders adherence to preventive measures. Some of these factors can be addressed.
Emergency departments, although rarely utilized for prevention, serve a diverse population and could serve as a strategic lever for educating the public about preventive health measures.
Personalized information, supported by a digital tool, could improve adherence to preventive measures. An interactive questionnaire was developed to tailor the information provided to patients based on their personal characteristics. The information delivered in this way would be more targeted for each patient and more likely to have a positive impact on the implementation of various preventive measures.
The purpose of this study is to determine whether a digital tool that provides personalized prevention information is more effective than general, non-personalized information in improving adherence among patients visiting the emergency department to the preventive measures recommended for them.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Christelle JADEAU
- Numero di telefono: +332 44 71 07 81
- Email: cjadeau@ch-lemans.fr
Backup dei contatti dello studio
- Nome: Cyrielle HOUALARD, MD
- Numero di telefono: +332 43 43 43 43
- Email: choualard@ch-lemans.fr
Luoghi di studio
-
-
Sarthe
-
La Flèche, Sarthe, Francia, 72205
- Pôle Santé Sarthe et Loir
-
Contatto:
- Cyrielle HOUALARD, MD
- Numero di telefono: +332 44 71 30 00
- Email: choualard@ch-lemans.fr
-
Le Mans, Sarthe, Francia, 72000
- Centre Hospitalier du Mans
-
Contatto:
- Cyrielle HOUALARD, MD
- Numero di telefono: +332 43 43 43 43
- Email: choualard@ch-lemans.fr
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Adult patients (≥ 18 years of age)
- Patients seen in the emergency departments of Le Mans University Hospital and the PSSL
- Patients who have given their free and informed oral consent
Exclusion Criteria:
- Patients who have previously participated in the study
- Patients with limited understanding of the French language
- Patients unable to give informed consent
- Individuals not enrolled in or not eligible for a social security program
- Individuals deprived of their liberty by judicial or administrative order
- Individuals receiving involuntary psychiatric care
- Individuals subject to a legal protective measure
- Pregnant or breastfeeding patients.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: A - Intervention
The first "intervention" group, designated A, is exposed to personalized information via a digital educational tool based on the characteristics entered for them.
|
The intervention involves providing personalized preventive health information regarding recommended preventive measures based on age, biological sex, weight, height, bedtime and wake-up times, the presence of chronic conditions, and tobacco or alcohol use.
|
|
Sperimentale: B - Control
The second "control" group, designated B, receives non-personalized information.
Using the same digital tool, the patient receives all the preventive health information without it being tailored to the patient.
The patient therefore does not see any information specific to him or her.
|
The intervention involves providing non-personalized preventive health information.
The patient receives all the preventive health information without it being tailored to the patient.
The patient therefore does not see any information specific to him or her.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
proportion of patients who adhered to at least 25% of the preventive measures
Lasso di tempo: 6-8 weeks after the intervention.
|
The primary outcome measure is the proportion of patients who adhered to at least 25% of the preventive measures for which they were eligible, as assessed 6-8 weeks after the intervention. Adherence is defined as the completion of a preventive measure or the initiation of steps leading to its completion in the short term |
6-8 weeks after the intervention.
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
The proportion of patients who adhered to each of the preventive measures studied.
Lasso di tempo: 6-8 weeks after the intervention.
|
6-8 weeks after the intervention.
|
|
The proportion of preventive measures taken by the patient, relative to the measures for which the patient is eligible.
Lasso di tempo: 6-8 weeks after the intervention.
|
6-8 weeks after the intervention.
|
|
The enrollment rate for each epidemiological subgroup (age, sex, whether the patient has a primary care physician, whether the patient has a chronic condition, socioeconomic status).
Lasso di tempo: 6-8 weeks after the intervention.
|
6-8 weeks after the intervention.
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- CHM-2025/S02/17
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .